FourThought Financial Partners’s AstraZeneca AZN Stock Holding History

FourThought Financial Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.7M	Buy	79,487 +3,989	+5%	+$769K	1.35%	22
2025 Q4	$13.9M	Buy	75,498 +1,993	+3%	+$350K	1.17%	25
2025 Q3	$11.3M	Buy	73,505 +1,777	+2%	+$269K	0.99%	31
2025 Q2	$10M	Buy	71,728 +20,893	+41%	+$2.93M	0.99%	34
2025 Q1	$7.47M	Buy	50,835 +5,907	+13%	+$855K	0.78%	41
2024 Q4	$5.89M	Buy	44,928 +922	+2%	+$129K	0.61%	45
2024 Q3	$6.86M	Sell	44,006 -423	-1%	-$68.3K	0.81%	44
2024 Q2	$6.93M	Buy	44,429 +57	+0.1%	+$8.58K	0.89%	39
2024 Q1	$6.01M	Buy	44,372 +14,161	+47%	+$1.88M	0.69%	45
2023 Q4	$4.07M	Buy	30,211 +1,316	+5%	+$171K	0.51%	55
2023 Q3	$3.91M	Buy	28,895 +1,617	+6%	+$221K	0.55%	52
2023 Q2	$3.9M	Buy	27,278 +2,155	+9%	+$317K	0.51%	57
2023 Q1	$3.49M	Buy	25,123 +292	+1%	+$39.3K	0.48%	63
2022 Q4	$3.37M	Buy	+24,831	New	+$3.11M	0.49%	57

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

FourThought Financial Partners's AZN Position: Q1 2026 in Review

FourThought Financial Partners increased its AstraZeneca (AZN) stake by 5.3% in Q1 2026, buying an estimated $769K and bringing the position to 79,487 shares worth $15.7M. The position accounts for 1.35% of the portfolio, ranked #22.

FourThought Financial Partners first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

FourThought Financial Partners held 79,487 shares of AstraZeneca worth $15.7M as of Q1 2026.
FourThought Financial Partners bought 3,989 AstraZeneca shares in Q1 2026, an estimated $769K.
AstraZeneca made up 1.35% of FourThought Financial Partners's portfolio in Q1 2026, its #22 holding.
FourThought Financial Partners first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on FourThought Financial Partners's 13F filing for Q1 2026, filed 7 May 2026.